ACUDIN – ACUupuncture and laser acupuncture for treatment of Diabetic peripheral Neuropathy: a randomized, placebo-controlled, partially double-blinded trial

Gesa Meyer-Hamme¹, Thomas Friedemann¹, Henry Johannes Greten²,³, Rosemarie Plaetke⁴, Christian Gerloff⁵ and Sven Schroeder¹*¹

Abstract

Background: Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus with significant clinical sequelae that can affect a patient’s quality of life. Metabolic and microvascular factors are responsible for nerve damage, causing loss of nerve function, numbness, painful sensory symptoms, and muscle weakness. Therapy is limited to anti-convulsant or anti-depressant drugs for neuropathic pain and paresthesia. However, reduced sensation, balance and gait problems are insufficiently covered by this treatment. Previous data suggests that acupuncture, which has been in use in Traditional Chinese Medicine for many years, may potentially complement the treatment options for peripheral neuropathy. Nevertheless, more objective data on clinical outcome is necessary to generally recommend acupuncture to the public.

Methods: We developed a study design for a prospective, randomized (RCT), placebo-controlled, partially double-blinded trial for investigating the effect of acupuncture on DPN as determined by nerve conduction studies (NCS) with the sural sensory nerve action potential amplitude as the primary outcome. The sural sensory nerve conduction velocity, tibial motor nerve action potential amplitude, tibial motor nerve conduction velocity, the neuropathy deficit score, neuropathy symptom score, and numeric rating scale questionnaires are defined as secondary outcomes. One hundred and eighty patients with type 2 diabetes mellitus will be randomized into three groups (needle acupuncture, verum laser acupuncture, and placebo laser acupuncture). We hypothesize that needle and laser acupuncture have beneficial effects on electrophysiological parameters and clinical and subjective symptoms in relation to DPN in comparison with placebo.

Discussion: The ACUDIN trial aims at investigating whether classical needle acupuncture and/or laser acupuncture are efficacious in the treatment of DPN. For the purpose of an objective parameter, NCS were chosen as outcome measures. Acupuncture treatment may potentially improve patients’ quality of life and reduce the socio-economic burden caused by DPN.

(Continued on next page)
Background
Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes mellitus with significant clinical sequelae and impact on patients’ quality of life [1, 2]. DPN manifests itself on the toes and progresses in a stocking distribution [3]. Nerve damage is related to hyperglycemia. However, various other mechanisms play a role in the pathogenesis of DPN [3]. These include elevated polyol pathway activity, advanced glycation end products (AGEs), oxidative stress, growth factors, impaired insulin/C-peptide action, and elevated protein kinase C activity. These may directly affect neuronal tissues as well as vascular structures, thus compromising nerve vascular supply [4, 5].

Clinical manifestations include paresthesia, burning sensations, and neuropathic pain as well as negative symptoms like hypesthesia, hypalgesia, and pallhypesthesia. These may contribute to balance problems and unsteadiness, leading to falls [6] and an increased risk of bone fractures and hospitalization [7]. Motor symptoms, for example muscle spasm and weakness occur less frequently [3]. DPN is associated with an increased risk of ulceration and amputation of the lower extremities as well as increased healthcare costs [8–10]. Nerve damage can occur on the myelin sheath as well as at the axonal level [11]. Differentiation is achieved by nerve conduction studies (NCS) [12]. Whilst neuropathic pain and paresthesia can be palliated by anti-convulsants, tricyclic antidepressant drugs or serotonin-noradrenalin re-uptake inhibitors [13], pharmacologic management of decreased sensation is generally ineffective, thus forming a gap in treatment strategies.

During the last decades, acupuncture has become an empirical complementary treatment option for DPN. It is recommended by the World Health Organisation [14] and the National Institute of Health [15] but treatment effectiveness is still under debate. Reviews concerning acupuncture for peripheral neuropathy (PN) have found that, despite the majority of studies reporting positive results, a reliable statement of effectiveness is not possible due to methodological limitations [16–22]. Randomized controlled, blinded clinical trials of adequate statistical power and design are still pending.

Whilst acupuncture concepts using proximal or systemic acupuncture points on upper and lower extremities failed to show efficacy [23], our pilot studies using the selection of local and distal points described here showed promising results for the treatment of DPN, chemotherapy-induced PN and PN of unknown cause(s). These studies have verified the improvement that can be found in subjective scales by means of NCS parameters [24–27]. Acupuncture has been shown to increase blood perfusion towards the periphery of the limbs following needle insertion [28]. The results of our pilot studies were potentially related to the acupuncture effect on the blood flow through vasa nervorum and dependent capillary beds supplying the neurons [26]. These findings are encouraging for setting up the framework of a clinical study of adequate sample size using strict methodological standards.

Definition of adequate controls for acupuncture
The development of appropriate designs for clinical acupuncture trials remains a methodological challenge. A major problem is the definition of placebo controls and blinding procedures, as the insertion of acupuncture needles is usually perceptible and visible.

Double-blinding of needle acupuncture has been achieved for immediate effects using invasive sham acupuncture concepts as control [29, 30]. However, this approach is problematic for long-term trials because of a possible overlap of specific as well as unspecific physiological and placebo effects. Sham acupuncture, at irrelevant or non-acupuncture points, was found to promote physiological stimuli due to an unspecific endorphin release in a range of 33–50%, exceeding the effect of a suggestive placebo therapy [31]. Hence, treatment with invasive sham acupuncture is not an inert placebo but an active treatment of unknown activity [32].

Accordingly, no reliable blinding methodology for needle acupuncture has been achieved so far for time spans of 10 weeks’ intervention. Differences in verum and placebo treatment patterns could not be accurately masked from the practitioner over time, creating the risk of bias [33].

Even shallow needling showed both specific and unspecific effects [34–36], evoking physiological responses similar to classical needle acupuncture and distorting the results [37].

To overcome these obstacles we include Laserneedle® acupuncture with multichannel red laser light into the ACUDIN study design. Laser needles are not inserted into the skin but merely placed on the surface of the...
acupuncture points; however, the therapeutic effects are of a similar dimension to those evoked by manual needle acupuncture [38]. The initial effect of laser acupuncture is mediated by the impact of ATP release from cutaneous mast cells [39, 40], which is considered comparable to the mechanical effect of needle acupuncture [41, 42]. Patients do not feel the activation of the laser needles as the radiation intensity is optimized for this purpose [43] and they cannot distinguish between verum and placebo laser [44]. Laser acupuncture is considered an appropriate means of control for acupuncture trials for evaluating the effect of needling per se [44].

**Methods/design**

**Trial design**

The aim of the ACUDIN trial is to examine if acupuncture and laser acupuncture have beneficial effects on NCS parameters, clinical scores and patient’s complaints in DPN as evaluated by standardized tests. A prospective, randomized, placebo-controlled, partially double-blinded, three-armed study design has been applied to the ACUDIN trial to compare the effects of classical needle acupuncture and laser acupuncture with those of placebo laser acupuncture.

Patients will receive 10 treatments over a period of 10 weeks. Each session will last 20 min. Neurological assessment, including NCS, is performed at baseline, week 6 and week 15 (Fig. 1).

**Trial personnel**

A total of four persons are involved in the ACUDIN trial procedure. The treatment is performed by the following health professionals: (i) experienced practitioners who are members of a German Physicians Society for Acupuncture. They have completed a standardized training course, undertaken formal accreditation by examination and a period of supervised medical experience required for administering the acupuncture interventions and were trained by Laserneedle® specialists for the implementation of multichannel laser acupuncture; (ii) two study nurses are involved in the treatment procedure as described below; and (iii) experienced neurologists, not involved in further study procedures, perform neurological assessments including NCS.

**Study population**

A total of 180 patients with DPN due to diabetes mellitus type 2 will be recruited from regional medical clinics, via the homepage of the operating institute, media reports, and advertisements.

**Inclusion criteria**

Participants who meet the following conditions will be included:

- Male or female aged > 18 years
- Confirmed diagnosis of diabetes mellitus type 2 (i.e., HbA1c ≥ 6.5% (48 mmol/mol) [45] and/or on diabetes medication for more than 1 year)
- Stable levels of HbA1c during the last 6 months (i.e., deviation < 1% (11 mmol/mol))
- Clinically confirmed diagnosis of DPN
- Pathologic results in NCS (i.e., sural SNAP < 10 μV, sural NLG < 42 m/s, tibial MNAP < 8 mV, tibial MNLG < 40 m/s) [46]
- Naive to laser acupuncture
- No prior acupuncture treatment for peripheral neuropathy

**Exclusion criteria**

Participants who present one or more of the following conditions are excluded:

- PN caused by conditions other than diabetes (e.g., alcohol abuse, chemotherapy, hereditary causes, chronic inflammatory or idiopathic PN, and others)
- History of epilepsy
- Coagulopathy or use of anticoagulants with bleeding time > 3 min, prothrombin time < 40%, platelet count < 50,000/μl, or PTT > 50 s
- Bacterial infection or other skin diseases at the lower extremities that impede acupuncture treatment
- Bone fracture of the lower extremities during the last 3 months
- Use of acupuncture during the last 3 months
- Opiate, analgesic, or drug abuse
- Psychiatric illnesses other than mild depression
- Incapacity in giving informed consent or in following the study instructions due to language disturbances, serious cognitive deficits, or lack of time
- Pregnant or breast-feeding women
- Current participation in other clinical studies

**Randomization procedure**

Recruited patients are randomized in a ratio of 1:1:1 into three parallel treatment groups of 60 participants: (i) classical needle acupuncture, (ii) verum laser acupuncture, and (iii) placebo laser acupuncture. Randomization is prepared beforehand with 180 identical closed envelopes, each, containing one of the three possible group allocations and a randomly generated four-number pseudonym code for further data processing. Randomization is performed by envelope lottery immediately prior to the first treatment session by study nurse 1. Patients and practitioners are only informed about the patients’ allocation to either
needle or laser treatment. However, patients do not know whether they will receive a true treatment or placebo. Group assignment will not be exposed until the final data analysis report is completed.

**Blinding**

A single-blind design is performed for needle acupuncture because of the difficulties of practitioner blinding for the needling procedure as specified above. A double-blind design is performed for laser acupuncture. Caregiver blinding for laser acupuncture is achieved by dividing the treatment into three steps:

1. Practitioner fixes the laser needles without activating them;
2. Study nurse 1 operates the laser device according to the randomization (verum or placebo);
3. Study nurse 2 removes the laser needles after treatment.

Practitioners and study nurses do not communicate concerning the patients’ group allocation. Further, the
investigator performing the neurological assessment and NCS does not know about the type of treatment given to the patient.

Regarding patients and the blinding procedure: the laser device is placed behind a folding screen so patients cannot see it. Patients wear laser protective glasses which make it impossible to perceive the laser light. They are informed that the laser device would emit visible and/or invisible laser beams and that the protection of the eyes is fundamental in any case because of the safety precautions as required by law. The laser needles are covered with a blanket. Acoustic functions of the laser device are deactivated prior to the study, so there is no difference between verum and placebo activation. This protocol will not be published in advance so patients cannot draw any conclusions concerning treatment allocations. Study participation is allowed only once.

For data transfer and processing, pseudonym codes are used in order to mask patient identity and treatment groups from outcome assessors and statisticians. The data is only matched after completion of statistical analysis.

**ACUDIN acupuncture protocol**

A total of 20 acupuncture points have been selected for the ACUDIN trial. All treatment sessions of needle and laser acupuncture are performed using the following point combination:

The 4 Bafeng points on both feet (Ex-LE-10) [47]. Needles are inserted to a depth of 3 to 5 mm and left in place without stimulation for 20 min. Laser needles are fixed with perforated plaster.

The 5 Qiduan points on both feet (Ex-LE-12) [47]. Needles are inserted to a depth of 1.5 to 2 mm and left in place without stimulation for 20 min. Laser needles are fixed with perforated plaster (Fig. 2).

The point Lianqiu on both legs (ST-34) [47]. Needles are inserted to a depth of 0.5 to 2.5 cm (depending on the diameter of the thigh) and left in place without stimulation for 20 min. Laser needles are fixed with perforated plaster.

Sterile single-use stainless steel needles size 0.2 × 15 mm are used for Qiduan and Bafeng points, respectively 0.3 × 30 mm for Lianqiu, both manufactured by Wujiang City Cloud & Dragon Medical Devise Co. Ltd, China.

**Laser acupuncture device**

Laser acupuncture is performed with Laserneedle® device (European patent PCT/DE 102006008774.7), a multichannel class 3B system which allows the simultaneous stimulation of individual point combinations through semiconductor laser diodes. Flexible optical light fibers conduct the laser light without loss, providing a high optical density at the distal end [40]. Wavelengths of 685 nm (red light) are emitted in continuous mode. Each channel has an optical power of 35 mW. Power density is 2.3 kJ/cm² per channel. The beam diameter is 500 μm and beam divergence at the end of
the laser needle is 9.5. Laser needles are placed at an angle of 90° directly on the skin, thus radiation reflection is minimized [43]. Laser needles are plugged in silicon adapters which are fixed with perforated plaster to the skin, so they stay in place without requiring the practitioner to stay with the patient. Temperature monitoring is not required because of extremely low heat development due to the weak absorption coefficient at 685 nm [48]. Previous investigations revealed no unintended side-effects of Laserneedle® treatment [40, 48]. The use of laser protection glasses is obligatory for both study nurse and patient. Two Laserneedle® machines with 10 laser needles each are used for the ACUDIN trial.

**Procedures**

**Verum needle acupuncture**

The treatment is applied according to the protocol with the patient in the supine position. The practitioner inserts the acupuncture needles after local disinfection of the skin. Needles are left in place for 20 min. They are carefully removed and disposed into a bedside sharps container at the completion of treatment by study nurse 2.

**Verum laser acupuncture**

The treatment is applied according to the protocol with the patient in supine position. The practitioner fixes the laser needles with perforated plaster after local disinfection of the skin. The patient’s legs and feet are covered and he/she wears laser protection glasses. The practitioner then leaves the room. Study nurse 1 enters the room and activates the laser emission by pressing at the soundless touch screen of the laser device according to the randomization schedule. Laser emission stops automatically after 20 min. Laser needles are removed and cleaned after use by study nurse 2.

**Placebo laser acupuncture**

Placebo laser acupuncture is performed as described for verum laser acupuncture with slight modifications. Study nurse 1 provides the same steps as for the verum treatment but without activating the laser, pressing an invalid point at the soundless touch screen of the laser device. Therefore, from the patient’s perspective, the procedure is identical to that used in the verum laser group.

**Nerve conduction studies**

The ACUDIN trial outcome measures are based on NCS parameters that are both objective and reproducible. These measures also provide quantitative data according to the Guideline for Diabetic Neuropathy [49, 50]. NCS are performed on both legs with a Neuropack-Sigma, MEB-9400, EMG/NCV/EP-System (Nihon-Khoden, Japan). Sural SNAP and tibial MNAP are measured on the first negative peak. All studies on NCS are done at room temperature (23 ± 1 °C). Sural NCS are done with standard orthodromic needle recording methods [51]. Tibial NCS are done with standard orthodromic surface electrode recording methods [51]. Skin temperatures are measured, and values of NCV are adjusted for the effect of temperature.

**Clinical examination**

Clinical examinations include sensory qualities such as the perception of pain and temperature, pallesthesia and two-point discrimination, patellar and Achilles reflexes, and gait qualities. The neuropathy deficit score (NDS) [52] and the neuropathy symptom score (NSS) [52] are part of the clinical assessment. Both are validated instruments for diagnosis and progress of DPN according to the Guideline for Diabetic Neuropathy [49].

**Questionnaires to collect participants’ opinions**

Common DPN-related symptoms will be recorded weekly by questionnaires using 11-point numeric rating scales (NRS) with the terminal descriptors “no complaint” and “worst complaint possible”. Whilst NRS are well validated for painful conditions [53], our questionnaires assess not only neuropathic pain but also tingling, burning pain, feeling of heat, feeling of cold, cramps, numbness, gait impairment, impairment of daily activities, sleep disturbances, and complaint frequency.

Table 1 summarizes the plan of data collection.

**Outcome measures**

**Primary endpoint**

The primary endpoint is the difference of the 15-week measurement minus baseline of the sural sensory nerve action potential amplitude (sural SNAP).

**Key secondary endpoints**

Secondary endpoints are the differences of the 15-week measurement minus baseline of the remaining NCS measurements:

- the sural sensory nerve conduction velocity (sural SNCV),
- tibial motor nerve action potential amplitude (tibial MNAP),
- tibial motor nerve conduction velocity (tibial MNCV).

Additional secondary endpoints will be obtained from the questionnaires:

- The differences in the 15-week measurement minus baseline of NDS, NSS, and NRS scores.

**Statistical analysis**

Major hypotheses tested are:

H0: The differences of the 15-week measurements minus baseline of sural SNAP in the two groups with classical
needle acupuncture or laser acupuncture are the same or smaller as in the control group.

vs.

H1:
The differences of the 15-week measurement minus baseline of sural SNAP in the groups with classical needle acupuncture or laser acupuncture are larger than in the control group.

In addition, for the two types of acupuncture treatment, two-sided hypotheses will be tested.

Data analysis
Hypotheses will be tested by using one-way analysis of variance (ANOVA), followed by Tukey post-hoc tests comparing the three groups pairwise.

A reasonable approximation to a normal distribution, according to the central limit theorem, can be assumed with the calculated sample size, allowing the use of parametric analysis. Deviations of the normal distribution will be tested and appropriate transformations will be performed. Homogeneity of variance will be tested with the Levene’s test.

The primary analysis will be performed with the intent-to-treat (ITT) population. Missing data will be imputed by the next-observation-carried-backwards option for initial values and last-observation-carried-forwards option for closing values. Legs with missing initial and closing data for the primary endpoint will be deleted from the analysis. The average values of both legs will be evaluated for patients with bilateral assessable measurements. For unilateral results, only the evaluable leg will be included in the analysis. The comparison between verum needle acupuncture and placebo laser acupuncture will be undertaken for validating the overall treatment effect of acupuncture. Verum laser acupuncture and placebo laser acupuncture will be compared for validating the specific treatment effect. The comparison of needle acupuncture to verum laser acupuncture will indicate the non-specific effect of needle acupuncture. Remaining NCS outcomes will be analyzed as described for the primary outcome. Multivariate analyses of the clinical secondary outcomes (NDS, NSS, and NRS) and their correlation to NCS parameters will be performed by linear regression models.

Baseline data and clinical characteristics will be presented as mean values to assess the baseline comparability of the intervention groups. Those patients who report changes of pain medication during the study will be excluded from data analysis relating to subjective pain scales. Statistical analysis will be done with the software SPSS (IBM SPSS Statistics 22) and OriginPro 9.

Sample size calculation
An average difference of 1 μV was considered functionally relevant for sural SNAP [54]. On the basis of a pilot study [24], a pooled standard deviation of 1.83 μV was calculated. By assuming that this standard deviation represents the best estimate of the actual standard deviation for each of the three groups in a regular three-arm parallel RCT design with complete follow-up, 54 patients per arm are required to detect the above difference for sural SNAP with an alpha of 0.05 and a power of 0.8. The assumption of a conservative 10% drop-out rate for patients randomized to any of the three arms increases the sample size to 60 patient per arm or 180 patients in total.

Power evaluations were performed with statistical analysis system (SAS) 9.2 for the above described statistical analysis (one-way ANOVA) and followed by post-hoc testing for the primary outcome.

Adverse events
Any adverse event and unexpected and unintended responses to the treatment reported by the patients are

---

**Table 1 Baseline and outcome parameters**

| Parameter | Baseline parameter | Blood parameter | Neurological assessment | NCS Parameter | Subjective Score |
|-----------|--------------------|-----------------|-------------------------|--------------|-----------------|
| Week 0    | Age                | HbA1c           | Clinical examination    | Bilateral amplitudes and NCV of nn. surales and tibiales | NRS            |
|           | Gender             |                 | NSS                     |              |                 |
|           | Weight             |                 | NDS                     |              |                 |
|           | (Diabetes and DPN) |                 |                         |              |                 |
| Week 6    | Change of medication | Clinical examination | Bilateral amplitudes and NCV of nn. surales and tibiales | NRS |
|           | HbA1c             |                 | NSS                     |              |                 |
|           |                  |                 | NDS                     |              |                 |
| Week 15   | Change of medication | Clinical examination | Bilateral amplitudes and NCV of nn. surales and tibiales | NRS |
|           |                  |                 | NSS                     |              | Adverse events  |
|           |                  |                 | NDS                     |              |                 |
| Weekly (treatment 1–10) | Change of medication | Clinical examination | Bilateral amplitudes and NCV of nn. surales and tibiales | NRS |

HbA1c = glycated hemoglobin; NCV = nerve conduction velocity; NDS = neuropathy deficit score; NRS = numeric rating scale; NSS = neuropathy symptom score; NCS = nerve conduction studies

---
recorded weekly with the NRS questionnaire. A causal relationship between treatment and adverse events will be evaluated using a six-grade-scale with the terminal descriptors 1 = definitely related and 6 = unknown. Possible adverse events related to acupuncture are hematoma, pain, nerve irritation, infection, and tiredness. An accidental irradiation of the eyes is regarded as the only relevant adverse event related to Laserneedle® treatment [40].

Timelines
Recruitment started in August 2011. Data collection started in January 2012. The ACUDIN trial is due to finish in 2017.

Discussion
DPN is a common complication of diabetes mellitus [1, 2]. Conventional medicine offers symptomatic pharmaceutical treatment for DPN masking neuropathic pain and paresthesia [13]. Unfortunately, these treatments are not always effective [3] and patients have to cope with medication side-effects [55]. Furthermore, there is no treatment for sensory loss, unsteadiness, and gait-impairment, causing a gap in medical care for diabetic patients and giving reason for extending the range of treatment options.

Acupuncture has been in use for decades for the treatment of DPN and positive results have been reported on the basis of empirical knowledge and a number of pilot studies [16–22]. However, the effectiveness of acupuncture is still under debate because of the lack of high-quality clinical research.

The peripheral nervous system has the ability of regeneration in relation to repair mechanisms and in the phenomena of spreading and sprouting [56]. In DPN, morphologic peripheral nerve regeneration is impaired and inadequate nerve regeneration contributes to the pathophysiologic mechanism of DPN [57]. However, the findings of our pilot study mention a possible improvement of NCS parameters following acupuncture treatment in DPN, indicating a certain amount of neural repair [25, 26]. Parallel to improved NCS, patients have experienced subjective improvement after acupuncture treatment compared to no specific treatment, but experienced the best medical care where positive and negative DPN-related symptoms were concerned [25]. The acupuncture protocol of the pilot studies using distal and local points on the lower extremities is taken as the basis for the ACUDIN study design because other concepts failed to show efficacy [23].

This paper presents the protocol for the prospective, randomized, placebo-controlled, partially double-blinded, three-armed clinical ACUDIN trial for testing the hypothesis that classical needle acupuncture and laser acupuncture improve objective NCS parameters, as well as clinical and subjective symptoms in DPN compared to placebo treatment. NCS has rarely been used as an objective parameter in acupuncture research [24–26, 58–62]. The ACUDIN trial is the first study using NCS as an evaluation method of acupuncture treatment of DPN of the lower extremities in the form of a randomized, partially double-blinded design type.

DPN may have a strong negative impact on patients’ quality of life [13]. However, healthcare systems can encompass increased use of resources and costs which may escalate according to the severity of the disease [8–10]. Acupuncture treatment can offer a cost-effective treatment option in comparison with conventional medicine [63, 64].

The findings of the ACUDIN trial may establish the value of complementary acupuncture treatment for the potential improvement of peripheral nerve function and clinical symptoms; in addition, the findings may also lead to a reduction of the socio-economic burdens caused by DPN.

Abbreviations
ACUDIN: ACUpuncture and Laser Acupuncture for treatment of Diabetic Peripheral Neuropathy; ANOVA: Analysis of Variance; DPN: Diabetic Peripheral Neuropathy; HbA1c: Glycated Hemoglobin; HMC: HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf, Germany; MNP: Motor Nerve Action Potential; MNCV: Motor Nerve Conduction Velocity; NCS: Nerve Conduction Study; NCV: Nerve Conduction Velocity; NDS: Neuropathy Deficit Score; NSS: Neuropathy Symptom Score; PN: Peripheral Neuropathy; RCT: Randomized Controlled Trial; SNAP: Sensory Nerve Action Potential; SNCV: Sensory Nerve Conduction Velocity; UKE: University Medical Center Hamburg-Eppendorf; WHO: World Health Organisation

Acknowledgments
Sarah Mirza for Fig. 2.

Funding
The ACUDIN trial is supported by the HanseMerkur Insurance Group and the Innovation Foundation, Hamburg (721.230–002) during the clinical phase. The Laserneedle GmbH (16548 Glienicker/Nordbahn) provides the laser device for the duration of the trial.

Availability of data and materials
The ACUDIN trial is registered at the German Clinical Trial Register (DRKS) under No. DRKS00008562, accessible at the trial search portal of the WHO (http://apps.who.int/trialsearch/).

Author’s contributions
SVS had the original idea for the ACUDIN trial. SVS and CG are responsible for the study design; definition of primary and secondary outcomes and preparation of the protocol. TF and RP are responsible for sample size calculation. SVS and HJG contributed to the determination of acupuncture point selection. GMH prepared the primary version of the manuscript. All authors have critically reviewed and approved the final version of the manuscript.

Authors’ information
GMH is a medical doctor employed at the HMC. TF is a doctor of biology employed at the HMC. HJG is a general practitioner; head of the Heidelberg School of TCM and professor at the University of Porto. R. Plaetke is a scientist for biostatistics at the UKE. CG is the director of the department of Neurology at the UKE and vice-director of the UKE. SYS is a neurologist and director of the HMC.
Ethics approval and consent to participate

The ACUDIN trial is structured in accordance with the Declaration of Helsinki. It has been approved by the institutional advisory board of the HanseMerkur Center (HMC) and the Ethics Committee of the Chamber of Physicians Hamburg (PV3518). Participants are invited to an assessment interview and give their written informed consent before randomization. Patients participate voluntarily and have the right to withdraw from the study at any time without stating reasons. Best medical care and pre-existent medication are maintained during the study period. Patients are allowed to use pain medication but asked to provide details of the nature of relevant medicines at each visit. Insurance for commuting-related accidents has been provided. Study documents are stored in a locked cupboard at the HMC for 15 years after termination of the trial.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 HanseMerkur Center for Traditional Chinese Medicine at the University Medical Center Hamburg-Eppendorf, Martinistrasse 52, House OSS, 20246 Hamburg, Germany. 2 Heidelberg School of Chinese Medicine, Karlsruher Str. 12, 69126 Heidelberg, Germany. 3 Department of Neurophysiology, Instituto di Ciencias Biomédicas Abel Salazar, University of Porto, Rua de Jorge Viterbo Ferreira n. 228, 4050 – 313 Porto, Portugal. 4 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany. 5 Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

Received: 9 October 2017 Accepted: 13 March 2018

Published online: 13 April 2018

References
1. Papanas N, Ziegler D. Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015. Rev Diabet Stud. 2015 Spring-Summer;12(1–2):48–62. doi: https://doi.org/10.1900/RDS.2015.12.48. Epub 2015 Aug 10.
2. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathy: a review. Pain Med. 2007 Sep(8 Suppl 2):S50–S62.
3. Boultin ALM, Malik RA, Arezzo JC, Sozenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1488–86.
4. Syze Van Dam P, Cotter MA, Bravenboer B, Cameron NE. Pathogenesis of diabetic neuropathy: focus on vascular mechanisms. Eur J Pharmacol. 2013;719(1–3):180–6. https://doi.org/10.1016/j.ejphar.2013.07.017. Epub 2013 Jul 17.
5. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia November. 2001;44(11):1973–88.
6. Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015;314(20):2172–81. https://doi.org/10.1001/jama.2015.13611.
7. Moseley KF. Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):128–35. https://doi.org/10.1097/MED.0b013e328350a6e1.
8. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002–results from the diabetic microvascular complications (DIMICO) study. Diabetes Res Clin Pract. 2008;81(2):223–30. https://doi.org/10.1016/j.diabres.2008.03.019. Epub 2008 Jul 7.
9. Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, van Nooten FE. Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract. 2015;109(2):215–25. https://doi.org/10.1016/j.diabres.2015.04.031. Epub 2015 May 6.
10. Gordois A, Scaffumb P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care June. 2003;26(6):1790–5.
11. Bosch EP, Mitsumoto H. Disorders in peripheral nerves. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston: Butterworth-Heinemann; 1991. p. 1720–6.
12. McLeod IG. Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1995;58:274–83.
13. Ziegler D, Fonseca V. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy. J Diabetes Complications. 2015 Jan-Feb; 29(1): 146–156. Published online 2014 Aug 28. doi: https://doi.org/10.1016/j.jdiacomp.2014.08.008. Epub 2014 Aug 28.
14. World Health Organization. Viewpoint on Acupuncture. Geneva, Switzerland, 1979.
15. National Institutes of Health. Acupuncture. NIH Consensus Statement Online 1997 Nov 3–5, 15(5):1–34.
16. Franco LC, Souza LAF, Da Costa Pessoa AP, Pereira LV. Nonpharmacologic therapies in diabetic neuropathic pain: a review. Acta Paulista de Enfermagem. 2011;24(2):284–8.
17. Bo C, Xue Z, Yi G, Zelin C, Yang B, Zixu W, Yajun W. Assessing the quality of reports about randomized controlled trials of acupuncture treatment on diabetic peripheral neuropathy. PLoS One. 2017(7):e0138461. https://doi.org/10.1371/journal.pone.0013846. Epub 2017 Jul 2.
18. Kowalczuk SA. Is Acupuncture An Effective Treatment For Diabetic Peripheral Neuropathy? (2012). PCOM Physician Assistant Studies Student Scholarship. Paper 74. Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA.
19. Meyer-Hamme G, Friedemann T, Xu LW, Epplé S, Schroeder S. Structured literature review of acupuncture treatment for peripheral neuropathy. J Acupunct Tuina Science. 2012;10(4):335–42. https://doi.org/10.1155/2013/516916.
20. Chen W, Yang GY, Liu B, Manheimer E, Liu JP. Manual acupuncture for treatment of diabetic peripheral neuropathy: a systematic review of randomized controlled trials. PLoS One. 2013(8):e73764. https://doi.org/10.1371/journal.pone.0073764. eCollection 2013.
21. Franconi G, Manni L, Schröder S, Marcetti P, Robinson N. A Systematic Review of Experimental and Clinical Acupuncture in Chemotherapy-Induced Peripheral Neuropathy. Evidence-Based Complementary and Alternative Medicine, Volume 2013, Article ID 516916. doi: https://doi.org/10.1155/2013/516916. Epub 2013 Jul 24.
22. Dmitrova A, Murchison C, Oken E. Effects of Acupuncture on Neuropathic Pain: A Systematic Review and Meta-analysis (P33.06) Neurology , 2015 vol. 84 no. 14 Supplement P33.06. https://doi.org/10.1016/j.aneuro.2015.08.011.
23. Rostock M, Jaroslavski K, Guettlin C, Ludtke R, Schröder S, Bartsch HH. Chemotherapy-induced peripheral neuropathy in cancer patients – a four arm randomized trial on the effectiveness of electro-acupuncture. Evidence-Based Complementary and Alternative Medicine. Volume 2013 (2013), Article ID 349653. doi: https://doi.org/10.1155/2013/349653. Epub 2013 Aug 28.
24. Schröder S, Liepert J, Remppis A, Gretten HJ. Acupuncture treatment improves nerve conduction in peripheral neuropathy. Eur J Neurol. 2007; 14(3):276–81.
25. Schröder S, Remppis A, Gretten T, Brakewitz F, Morcos M, Gretten HJ. Quantification of acupuncture effects of peripheral neuropathy of unknown and diabetic cause by nerve conduction studies. J Acupunct Tuina Sci. 2008;6:312–4.
26. Schroeder S, Epiple S, Bey A, Hu W, Brakewitz F. Adjuvant acupuncture treatment improves neuropathic pain in peripheral neuropathy and induces neural regeneration. Eur J of Pain Supplements. 2011;14(4):146-130.
27. Schroeder S, Meyer-Hamme G, Epiple S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30(1):4–7. https://doi.org/10.1136/ajpm.2011-010034. Epub 2011 Dec 5.
28. Litscher G, Wang L, Huber E, Nilsson G. Changed skin blood perfusion in the fingertips following acupuncture needle introduction as evaluated by laser Doppler perfusion imaging. Lasers Med Sci. 2002;17(1):19–25.
29. Hauer K, Wendt I, Schwenk M, Rohr C, Oster P, Gretten J. Stimulation of acupoint ST-34 acutely improves gait performance in geriatric patients during rehabilitation: a randomized controlled trial. Arch Phys Med Rehabil. 2011;92(1):7–14. https://doi.org/10.1016/j.apmr.2010.09.023.
